Experience of a medicines reference-pricing model by Rothberg, A D et al.
ORIGINAL ARTICLES
While post-apartheid South Africa has enjoyed single-digit
inflation for most of the past 8 years, so-called medical
inflation in the private sector has generally been around 10%
each year.  This is shown for the period 2000 - 2002 in Fig. 1.
The increase in medical inflation over consumer price index
(CPI) has been evident in most benefit categories, but mainly in
the areas of medicines, hospitalisation and specialist care.  The
inflation statistics may be expressed as a figure for all
categories or for specific categories, e.g. in the case of
medicines, as the administrator's overall annual increase in
expenditure on medicines, as the average annual increase at
member level, as the increase in cost of a standardised ‘basket’
of drugs, or as the cost increase of the drugs most abundantly
or commonly used each year.  These different measures of
medicines inflation as measured in the Medscheme
environment (and therefore not necessarily representative of
the industry) are summarised in Table I (data from Medscheme
Data Warehouse).
This phenomenon of medical inflation is not peculiar to
South Africa, and as has happened in other countries, national,
regional and local strategies have been devised to contain the
cost increases.  Kanavos1 has categorised these strategies as
being targeted at manufacturers (supply-side measures),
physicians and pharmacies (proxy demand-side measures) and
patients (demand-side measures).  Table II provides detail of
the possible components at each level, and for followers of the
developments in managed care in this country since the early-
to-mid 1990s, it will be obvious that while demand-side and
proxy demand-side control measures have been in place, little
has been done in terms of targeting manufacturers.
This gap in supply-side management was addressed by
Medscheme's Medicines Management and Interpharm teams in
2001, and was followed by the introduction of a reference-
pricing model in mid-2002.  The model, known as the
Medscheme Price List (MPL), recognises that the South African
Medicines Control Council takes responsibility for maintenance
of generic medicines standards, and given that registered
generic medicines are regarded as bio-equivalent to the original
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Objective. To measure the impact of a medicines reference-
pricing programme covering items for which appropriate
generic equivalents are available.  
Design. The list of covered items was continuously monitored
and updated by clinicians and pharmacists employed by
Medscheme, and was published as the Medscheme Price List
(MPL).  Prospective and retrospective analyses of prices of
medicines covered by the MPL were carried out and the effect
of the programme on expenditure by medical schemes was
measured.
Results. The programme had an immediate effect on the rate
of medicines inflation after implementation as a result of
switching from original or branded products to generic
medicines or switching from higher-priced to lower-priced
generic equivalents.
Conclusion. Over the past few years Managed Care has
focused on strategies aimed at reducing utilisation of health
care services and/or benefits by members of medical
schemes.  These strategies have largely been directed at
members and health care providers, with little attention paid
to suppliers (e.g. the pharmaceutical industry). This study has
shown that a supplier-directed strategy has merit and is
capable of substantially reducing expenditure on medicines.
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Fig. 1. Measures and magnitude of medical inflation v. consumer
price index (CPI) 2000 - 2002.
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product, Medscheme introduced a programme whereby
trustees of medical schemes could elect to pay up to a specified
price per group of ‘genericised’ medicines, provided that at
least two equivalents were freely available below that price,
unless only one generic equivalent for the brand existed or the
price differential between two available generics was too large.
The system allows some interchanges, e.g. between tablets and
capsules, and between salt forms of ingredients.  Members
would always be free to purchase more expensive generic,
original or branded products, but such purchases would be
subject to a co-payment.   After a period of member and
provider education (doctors and pharmacies) for schemes that
had signed up, the programme ‘went live’ on 1 May 2002.  The
following review and analysis represents the results of the
programme after 1 year.
Subjects and methods
The relevant time frames for the study were January to end-
April 2002 (T1), May to December 2002 (T2) and May 2002
until end-April 2003 (T3).  The first period did not extend
further back than January 2002 to minimise the confounding
effect of new-year price increases on measurement of pre-MPL
medicines inflation in 2002.  The second time period (May-
December 2002) was necessary because of the two-phased
enrolment of medical schemes onto the MPL programme
(because certain schemes chose an initial wait-and-see
approach before signing up).  The third time period covered
the 12-month period of major interest, i.e. 1 year from the time
of MPL implementation (MPLI).
The Medicines Management Team (MMT) identified the
range of products eligible for inclusion in the programme:  All
medicines for which generic equivalents existed were
considered for inclusion in the MPL, with the exception of
products listed by the Medicines Control Council as non-
substitutable. The primary principle applied in grouping
products was ‘generic similarity’, as opposed to ‘generic
equivalence’. This principle requires the following. 
1. That all products in the same group be exactly the same in
terms of all active ingredients.
Table I.  Alternatives for reporting on medicines inflation 
Year-on-year change (%)             
Inflation  measure 2000 - 2001 2001 - 2002 Source Limitations
Administrator's total –12.4 6.5 Medscheme Data This figure will change according 
annual expenditure  Warehouse to changes in membership numbers
Annual expenditure per 11.5 12.9 Medscheme Data Most reliable, but influenced by
member per month Warehouse benefit design changes and by
members changing to lower
options between years
Cost of common  basket 9.6 5.7 Medscheme Data Theoretical exercise that does not 
of medicines Warehouse track what is actually used, instead
tracks what happened to last year's
basket
Cost of most commonly 14.6 9.7 Medscheme Data Tracks cost of medicines actually
used medicines Warehouse used but does not take volumes into
account; tracks each year's top
basket
Table II.  Strategies to control medicine prices and costs1
Category Strategies
Supply-side management Free pricing, direct price controls, cost-plus, cost pricing, average pricing, 
internal price comparisons, profit control, reference pricing, positive or 
negative lists
Proxy demand management Budgets for doctors, generic policies, practice guidelines, monitoring 
and authorising behaviour, disease management programmes
Demand management Co-payments, health promotion programmes, patient-initiated therapy
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2. That all products in the same group have the same
strength and amount of active ingredients, with permissible
variation in terms of: (i) salts/esters of the active ingredients;
(ii) inactive ingredients; (iii) the formulation of the product (i.e.
capsules versus tablets); and (iv) the dosage regimen (i.e. twice
a day versus once a day).
Sustained- or modified-release formulations were grouped
separately from instantaneous formulations only if clinical
evidence supported a significantly improved or different
clinical outcome.
The initial MPL list at the time of MPLI included 2 165
product lines, which was increased to 2 273 during T3 as new
products entered the market.
Medicines inflation in 2002 was measured for the initial
basket of products and divided into two time periods covering
T1 and T2 to measure the impact of MPL on the pricing of
medicines.  The average cost per unit of drug was measured
for both MPL-eligible and ‘non-eligible’ drugs.  The ‘non-
eligible’ group included all medicines other than the 2 165
ultimately covered by the MPL.  Price movement of each
product was also calculated based on prices at MPLI versus
those at the end of T3.  In order to adjust for both new
products launched and product discontinuations, only those
product lines listed on the MPL throughout the T3 period
(1 530 product lines), were taken into consideration in the
overall inflation study. 
The agreement with medical schemes was to calculate
savings on the basis of the difference between the published
list price of the prescribed drug and the MPL reference price
for the relevant group of products.  For schemes that had
previously made use of the MMAP (Maximum Medical Aid
Price — MediKredit ) reimbursement threshold, the MPL
savings were reflected as the additional savings gained.
Implicit in the latter statement is the difference between
MMAP and MPL — the former largely tracks medicines prices
and sets a reimbursement threshold, while the latter more
aggressively recognises lowest prices and promotes
competition around that price.  MPL savings were therefore
calculated as the difference between the MPL reference price
and the MMAP reference price for the product at the time of
treatment.  This method of calculating savings underestimates
the full impact of the programme since greater compliance at
member and provider level will eventually result in less ‘re-
pricing’ to MPL and therefore lower savings.  Savings were
expressed on a per-member-per-month (pmpm) basis where
‘member’ applies to the principal member.  This convention is
due to schemes buying services on a pmpm basis and wanting
to offset any managed care savings against this fee.
It should be noted that the MPL process is an extremely
dynamic one.  The MMT is required to monitor price
movement of all products and continually adjust the MPL
threshold to conform to the original criteria for coverage.  The
team also engages in meetings with manufacturers of generic,
branded and original products who become concerned about
losing market share and request product-specific data.  In
several cases these meetings become price negotiations which
result in significant price reductions.  
Finally, during the member and provider education phases it
was made clear that any adverse events considered to be a
consequence of the programme could be reported to the MMT,
and where necessary, appropriate steps would be taken. This
would include the provision to override the co-payment for a
non-MPL drug based on clinical justification.
Results
Thirteen of Medscheme's schemes (representing 982 883 lives)
took the decision to apply the MPL as of 1 May 2002.  Several
others delayed the decision until 2003, preferring to wait for an
indication of the impact of the programme.  At this stage,
results can be expressed in terms of savings impact on all
medical schemes, and for 2002 also subdivided into impact on
contracted and non-contracted schemes.  
The MPL as introduced in 2002 covered 2 165 product lines.
The first indication of impact was noted in the medicines
inflation rate pre- and post-implementation for the group of
MPL-eligible drugs (Fig. 2). 
Whereas the inflationary increase for products on the MPL
was 7.5% during T1, the rate fell to 1.05% during T2.  Analysis
of price movement for the total group of MPL-eligible products
for the 12-month period after MPLI (i.e. T3) showed that 19.6%
of products dropped prices (mostly in the 0 - 10% range), 16.8%
increased by up to 10%, 19.5% by 11 - 15%, 7.8% by 16 - 50%,
1.7% up to 100% and 1.0% by more than 100%.  However, most
notable was that 33.7% of products held their price constant
between the months of May 2002 and end-April 2003.
Most of the downward price movements were related to
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Fig. 2. Cost increases in the MPL-eligible group of medicines before
and after MPL implementation. (The solid line represents the full
group of medicines for which generics were available, while the
dashed line represents the lowest-priced MPL set as defined in the
text.)
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generic products ‘jockeying’ for position and lowering price in
order to be covered fully by the MPL without additional cost to
members. However there were some notable cases in which an
original product that had steadfastly held its price even after
patent expiry, dropped in price after MPLI (Fig. 3).  
One year after MPLI the average reference unit price for all
groups on the MPL as determined by the MMT had increased
by only 2.18% from R3.21 to R3.28  whereas the average unit
price for all products affected by the MPL had increased by
3.63% from R4.40 to R4.56 (Fig. 4).
When one examines the implications of these changes at
medical scheme level it becomes clear that MPL had an
immediate and significant impact (Fig. 5). 
Subdividing schemes’ medicine expenditure into acute and
chronic components for 2002 presents an additional and
convincing picture of a steady decline during T2 after the usual
and expected annual increase in medicine costs during T1 (Fig. 6).
The cumulative savings for contracted schemes were
substantial and considerably more than they had enjoyed
previously using only the MMAP model (Fig. 7).
In considering other reasons for the decline in medicines
expenditure after MPLI in May one should note that May is too
early in the year to invoke seasonality or benefit exhaustion as
causes.  Converting all of the above to a pmpm figure for
overall medicines inflation within the Medscheme group of
schemes for the periods January - April 2002 v. January - April
2003  yields a result of only 4.85%, substantially below that
experienced in previous years.
Finally, in accordance with the undertaking to remove any
Fig. 3. Influence of the MPL on simvastatin. (The figure shows how
the original product dropped in price to the MPL level, followed by a
reduction in the price of the generic equivalent to below MPL
threshold.)
Fig. 4. Increase in MPL reference price v. all MPL-eligible products:
2003 v. 2002. (Note the small year-on-year increase for both groups
but the even smaller increase in the MPL group of medicines.)
Fig. 5. Average acute and chronic medicines expenditure (Rand
pmpm) for all Medscheme schemes before and after MPL
implementation. (Note the approximation of the 2002 and 2001 lines
after MPL implementation.)
Fig. 6. Acute and chronic medicine expenditure before and after MPL
implementation (cumulative Rand pmpm, i.e. summed for the
schemes in the sample). (Note the decrease in pmpm spent after MPL
implementation.  Savings are greater for acute medicines than for
chronic.) 
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MPL products consistently found to be associated with any
adverse events or effects, following a small series of consistent
reports from members and providers it was necessary to
remove one single item from the diuretic category.
Discussion
The views of health economists who have experience of
interventions targeted at containing medicines inflation are
quite varied.  Whereas British Columbia has seen substantial
savings since the introduction of reference pricing in 1997,2-4
some European analysts are concerned about the sustainability
of supply-side, price-related interventions,5-7 especially if they
are introduced in isolation (i.e. without also addressing the
demand side).  Authors refer to the unintended consequences
of reference pricing8,9 and violation of market principles,5 and
urge health policy makers to avoid forfeiting quality care for
the sake of short-term savings and to evaluate fully cost
effectiveness of competing products.8,10,11 Yet these and other
reviews12,13 also indicate that the Medscheme experience as
presented in this report is not unique; for example de Vos12 in a
report on the impact of reference pricing in the Netherlands
showed that lowering of Dutch prices to the mean of
pharmacy-buying prices in the UK, France, Belgium and
Germany had an extremely positive effect, improved discounts
for pharmacists, enhanced opportunities for companies to
compete on the basis of price, created a cost-conscious demand
side, and made it easier for new participants to enter the
system.  Ioannides-Demos and colleagues7 state quite simply
that reference pricing appears to be one of the few strategies
likely to be effective in getting doctors to use the least
expensive drugs as first choice.  Darba and Rovira’s14 view is
that for Europe, discount and reference pricing could be the
most feasible options, and Grootendorst et al.2 endorse the view
that savings are mostly due to better prices.
Table II provides a summary of strategies that managed care
organisations and/or administration companies might bring
into play to influence the price and utilisation of services or
benefits.  Medical schemes administered by Medscheme have
made use of several of the strategies in the ‘demand’ and
‘proxy demand’ categories, but until development and
implementation of the MPL had not engaged in any supply-
side interventions.  The present review was undertaken to
evaluate the additional impact of the MPL, and certainly after
this initial assessment there is little doubt about the success of
the initiative. 
In the first instance it is obvious that the MPL has had a
significant effect on medicines prices, and even though there
are ‘only’ about 1 500 products on the list, there is a clear
impact on total medicines expenditure, irrespective of whether
or not a scheme had registered for implementation of MPL
(Figs 5 and 6)   For the most part these results were achieved
despite some expectations of prescribing of non-substitutable
products by providers to avoid MPL ‘interference’, and/or
concerns about orchestrated and sustained challenges from
manufacturers and providers.   
Schemes that did not register for the MPL programme
nevertheless enjoyed the benefit of lower medicine prices (and
this would have applied to all medical schemes and their
members, whether administered by Medscheme or by other
entities), while MPL-registered schemes gained the additional
advantage through awareness at member and provider level
that use of a non-eligible product would attract a co-payment. 
The willingness of manufacturers to drop prices is most
likely an indication of how much ‘fat’ there has been in the
system, but it is also an indication of the ability of a major
player such as Medscheme to exert influence to the advantage
and benefit of consumers both within and outside of the
medical schemes environment.  What is even more exciting has
been the willingness of some manufacturers of original and
branded products to drop prices to meet or at least
approximate MPL levels.
No article of this nature can be complete without some
comment on quality of care, and no programme of this nature
can be implemented without some concern about the views of
the manufacturers, providers and consumers.  Consequently,
everything was done to reassure scheme trustees as well as the
other stakeholders that call centres would be ready, willing and
able to note and then forward concerns to the appropriate
parties within the organisation.  Suffice to say that the volume
of negative responses has been extremely low, and as
previously stated, in the single instance of adverse effects of
MPL substitution, the MMT had no hesitation in removing the
product from the list.
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Children acquire HIV-1 infection through vertical transmission
occurring in utero, during the birth process, or postnatally
through breast-feeding.1 Other well-recognised routes include
contaminated blood products and sexual abuse.2,3
There are a number of reports from both First- and Third-
World settings of unusual HIV transmission.4-6 These include
nosocomial incidents where needles had been reused and
others where the cause was less obvious, but where access to a
‘sharps’ container was possible.  HIV infection in the
household was also documented.4-6
Unexplained HIV-1 infection in children — documenting
cases and assessing for possible risk factors
R Hiemstra, H Rabie, H S Schaaf, B Eley, N Cameron, S Mehtar, A Janse van Rensburg, M F Cotton
Background. In the year 2000 we reported possible horizontal
transmission of HIV-1 infection between two siblings. An
investigation of three families, each with an HIV-infected
child but seronegative parents, permitted this finding. Sexual
abuse and surrogate breast-feeding were thought unlikely.
The children had overlapping hospitalisation in a regional
hospital. Since then several cases of unexplained HIV
infection in children have been reported. A registry was
established at Tygerberg Children’s Hospital for collection of
data on the extent of horizontal or unexplained transmission
of HIV in children. 
Study design. Retrospective chart review.
Results. Fourteen children were identified, 12 from the
Western Cape and 1 each from the Eastern Cape and
KwaZulu-Natal. Thirteen (92%) had been hospitalised
previously. In the Western Cape, children had been
hospitalised in 8 hospitals. Ten of 13 (77%) were admitted as
neonates and 9 of 13 (69%) had 2 or more admissions.
Intravascular cannulation and intravenous drug
administration occurred in all but 2 children before HIV
diagnosis. 
Conclusion. We have confirmed HIV infection in a number of
cases where the source of infection has been inadequately
explained. Circumstantial evidence supports but does not
prove nosocomial transmission. Further studies and
identification of medical procedures conducive to the spread
of HIV are urgently needed.
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